



AF
IPW

AMENDMENT TRANSMITTAL LETTER

Docket No.
CCI-027CN

Application No.
10/671747-Conf. #9353

Filing Date
September 26, 2003

Examiner
D. R. Rao

Art Unit
1624

Applicant(s): Peter Martin FISCHER et al.

Invention: INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	54	- 57 =		x	
Independent Claims	5	- 5 =		x	
Multiple Dependent Claims (check if applicable) <input checked="" type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

Large Entity

Small Entity

No additional fee is required for this amendment.

Please charge Deposit Account No. _____ in the amount of \$ _____. A duplicate copy of this sheet is enclosed.


A check in the amount of \$ _____ to cover the filing fee is enclosed.

Payment by credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 12-0080 as described below. A duplicate copy of this sheet is enclosed.

Credit any overpayment.

Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.



Cynthia M. Soroos
Attorney/Agent Reg. No.: 53,623

Dated: March 14, 2006

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400

Express Mail Label No.: EV 608 866 469 US Dated: March 14, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Peter Martin Fischer *et al.*

Serial No.: 10/671,747

Filed: September 26, 2003

For: Inhibitors of Cyclin Dependent Kinases as Anti-Cancer Agent

Attorney Docket No.: CCI-027CN

Group Art Unit: 1624

Examiner: Deepak R. Rao

MS After Final
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL

Dear Sir:

This is in response to the Final Office Action mailed from the United States Patent and Trademark Office in the above referenced patent application on January 4, 2006. No extension of time is required at this time. Please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 16 of this paper.